Bluejay Diagnostics Updates Corporate Address and Phone

Ticker: BJDX · Form: 8-K · Filed: 2024-12-04T00:00:00.000Z

Sentiment: neutral

Topics: corporate-address, contact-information

TL;DR

Bluejay Diagnostics moved offices and got a new phone number.

AI Summary

On December 3, 2024, Bluejay Diagnostics, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 360 Massachusetts Avenue, Suite 203, Acton, MA 01720. The company's telephone number has also been updated to (844) 327-7078.

Why It Matters

This filing provides updated contact and location information for Bluejay Diagnostics, Inc., which is important for investors, partners, and regulatory bodies to maintain accurate records.

Risk Assessment

Risk Level: low — The filing is administrative and does not involve financial performance, significant operational changes, or legal issues.

Key Players & Entities

FAQ

What is the new address for Bluejay Diagnostics, Inc.'s principal executive offices?

The new address for Bluejay Diagnostics, Inc.'s principal executive offices is 360 Massachusetts Avenue, Suite 203, Acton, MA 01720.

What is the updated telephone number for Bluejay Diagnostics, Inc.?

The updated telephone number for Bluejay Diagnostics, Inc. is (844) 327-7078.

On what date was this 8-K report filed?

This 8-K report was filed on December 4, 2024, with the earliest event reported on December 3, 2024.

What is the state of incorporation for Bluejay Diagnostics, Inc.?

Bluejay Diagnostics, Inc. is incorporated in Delaware.

What is the SIC code for Bluejay Diagnostics, Inc.?

The Standard Industrial Classification (SIC) code for Bluejay Diagnostics, Inc. is 3841, which corresponds to Surgical & Medical Instruments & Apparatus.

Filing Stats: 440 words · 2 min read · ~1 pages · Grade level 10.4 · Accepted 2024-12-04 17:26:38

Key Financial Figures

Filing Documents

01. Other Matters

Item 8.01. Other Matters. On December 3, 2024, Bluejay Diagnostics, Inc. (the "Company") received a letter from the Listing Qualifications Department of The Nasdaq Stock Market notifying the Company that, based on the closing bid price of the Company's common stock having been at least $1.00 per share for the required period, the Company has regained compliance with Nasdaq Listing Rule 5550(a)(2) and the minimum bid price deficiency matter previously disclosed by the Company on March 4, 2024 is now closed. 1 SIGNATURE Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Bluejay Diagnostics Inc. By: /s/ Neil Dey Neil Dey President and Chief Executive Officer Dated: December 4, 2024 2

View on Read The Filing